N/A N=131 The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study
Post-Infarction Ventricular Septal Defect
Primary: Effectiveness Endpoint 1: Technical Success — 76 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=8 Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Parkinson Disease
Primary: Aim I: Investigate the Effect of GOCOVRI™ on Activity Levels in People With Parkinson's Disease (PD) and Levodopa Induced Dyskinesia (LID) Measure: Number of Walking…
Phase 2 N=64 Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Diffuse Large B-Cell Lymphoma
Primary: Overall Response (OR) Rate — 36 Participants
Phase 2 N=48 Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Pancreatic Cancer · Periampullary Adenocarcinoma
Primary: Late Gastrointestinal Toxicities — 13 Participants
N/A N=1,328 Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US
Covid19
Primary: Total Number of Tests Among Network Members Referred for COVID Testing (Network Tested). — 444; 437; 196; 206 Participants
Phase 1 N=11 APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
Metastatic Malignant Neoplasm in the Brain · Metastatic Solid Neoplasm · Recurrent Colorectal Carcinoma
Primary: Number of Adverse Events Common Terminology Criteria for Adverse Events Version 4.0 — 0; 1; 8; 0 Participants
Phase 1 N=21 Increasing Activity for Veterans With PTSD
Stress Disorders, Post-Traumatic
Primary: Recruitment — 24 Participants
Phase 2 N=21 Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder
Posttraumatic Stress Disorder · Stress Disorders, Post-Traumatic
Primary: Clinician Administered PTSD Scale (CAPS-5) — 42.8; 42.9; 15.2; 10.1 score on a scale
Phase 1 N=27 Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine
Group B Streptococcus Infection
Primary: Treatment Emergent Adverse Events — 10; 7; 10; 4 Participants
Phase 3 N=43 A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age
Presbyopia
Primary: Overall Composite Driving Z Score Approximately 1 Hour After Study Intervention Instillation — 0.118; -0.121 Z-score — p=0.0006
N/A N=236 Telephone Support for Metastatic Breast Cancer Patients
Metastatic Breast Cancer
Primary: Fatigue Interference Subscale of Fatigue Symptom Inventory — 2.96; 3.66; 3.24; 3.43 units on a scale — p=.018
N/A N=24 The Emotional, Physical and Cognitive Benefits of Purposeful Green Space Activities on Seniors
Loneliness · Social Isolation · Mood
Primary: Loneliness (Time 1) — 4.08; 5; 3; 3 units on a scale
Phase 1 N=15 Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
Prostate Cancer
Primary: Dose-dependent Toxicity — 0; 2; 0; 2 participants
Phase 3 N=120 A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution
Anesthesia, Local
Primary: The Percentage of Patients Who Experienced Ocular Anesthesia Following Treatment of AG-920 Compared to Placebo at 5 Minutes — 50; 11; 10; 49 Participants
Phase 1 N=8 A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.
Healthy
Primary: Maximum Observed Concentration (Cmax) of Cis-Ceftibuten (CTB): Part 1 — 18170; 25470; 30510; 27120 Nanogram per milliliter (ng/mL)